Wedbush Cuts Earnings Estimates for TScan Therapeutics
TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Equities researchers at Wedbush cut their FY2025 EPS estimates for shares of TScan Therapeutics in a research note issued to investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.98) per share for the year, down from their prior forecast […]
12 Mar 06:41 · The Markets Daily